Lofexidine

Lofexidine

SCHEMBL3500726

CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2C

The experimentally established mechanism targets of Lofexidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADRA2A known ✓ P08913 16/20 0.97
ADRA2B known ✓ P18089 16/20 0.97
ADRA2C known ✓ P18825 16/20 0.97
HTR1A P08908 2/20 0.97
SLC6A4 P31645 1/20 0.97
ADRA1A P35348 1/20 0.97
OPRK1 P41145 1/20 0.97
KCNH2 Q12809 1/20 0.97
MAOA P21397 6/20 0.60
MAOB P27338 6/20 0.60
NISCH Q9Y2I1 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lofexidine SCHEMBL124601 1.00 ADRA2A (0.97) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Levlofexidine SCHEMBL947241 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL48960 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Dexlofexidine SCHEMBL124602 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL678553 0.97 ADRA2A (0.97) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL22616208 0.97 ADRA2A (0.97) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL22616152 0.91 ADRA2A (0.85) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL22616113 0.91 ADRA2A (0.85) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL22616174 0.91 ADRA2A (0.85) ADRA2AADRA2BADRA2CHTR1ASLC6A4
Lofexidine SCHEMBL22616216 0.90 ADRA2A (0.82) ADRA2AADRA2BADRA2CHTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160369237-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECH INC (US) 2016-12-22 US disclosed
US-20100184033-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY Lineage Cell Therapeutics, Inc. 2010-07-22 US disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 US disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 EP disclosed
US-20080070303-A1 Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement ADVANCED CELL TECHNOLOGY 2008-03-20 US disclosed
WO-2007062198-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECHNOLOGY, INC. (US) 2007-05-31 WO disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 WO disclosed